Inherited disorders of trafficking

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Tuesday, November 14, 2023
CNS, DSM-IV codes, DNA, Conditional sentence, Janssen Pharmaceuticals, Subthalamic nucleus, Patient, Research, ESGCT, FTD, Capsid, Quality control, Congress, I&I, Safety, Treatment, IND, Immunology, Inherited disorders of trafficking, ROFN, Evercore, Genome, STN, Central nervous system, Martin Lipton, Frontotemporal dementia, Xerostomia, Johnson & Johnson, MIA, GMP, Gene, BLA, Commercial, Insurance, Parotid gland, ALS, Parkinson's disease, Clinical trial, Obesity, QC, File, CGMP, RIX, Pharmaceutical industry, Vaccine, Cryptocurrency, Birth control, Sanofi, Janssen, Inflammation

Bota-vec for the Treatment of XLRP:

Key Points: 
  • Bota-vec for the Treatment of XLRP:
    Enrollment completed in second quarter 2023 in the pivotal Phase 3 LUMEOS clinical trial in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
  • In September 2023, the IND for bota-vec for the treatment of XLRP was transferred from MeiraGTx to Janssen.
  • Results from AQUAx Phase 1 open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as a treatment for RIX and parotid gland hypofunction presented at ESGCT 2023 Annual Congress on October 26, 2023.
  • License revenue was $5.1 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights

Retrieved on: 
Friday, December 8, 2023
Attention, Novo Nordisk, Research, Conditional sentence, AstraZeneca, Prevalence, Gene editing, Takeda Pharmaceutical Company, Proteomics, Gilead Sciences, Biotechnology, Sanofi, Bayer, Genomics, DSM-IV codes, Genetic engineering, BRD, Cas9, Inherited disorders of trafficking, Tissue engineering, GSK, Therapy, Novartis, Chronic condition, Eli Lilly and Company, Drug discovery, Cancer, GSK plc, Amgen, Growth, Pfizer, Bristol Myers Squibb, Hospital, Diabetes, Biogen, AbbVie, Drug development, Cabozantinib, Pharmaceutical industry, Generic drug, Fine chemical

Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.

Key Points: 
  • Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.
  • This has led to the introduction of innovative products and treatment options in the market, thereby driving the growth of the Red Biotechnology Market .
  • The market for biopharmaceuticals is expected to experience significant growth in the red biotechnology market.
  • The other applications, including animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, and agricultural biotechnology, also show potential growth.

Pentec Health and Lobe Sciences Announce Exclusive Distribution Agreement, Initial Availability of Altemia, First U.S. Medical Food for People With Sickle Cell Disease

Retrieved on: 
Thursday, September 21, 2023
Molecule, Insurance, CSE, GLEN, DHA, SCD, Health, Health equity, Inherited disorders of trafficking, Research, Biomarker, History, Life expectancy, Pain, Pharmacist, Patient, Physician, Swelling, Nursing, Sickle cell disease, Mouse, Blood cell, Rare, Disease, Pharmaceutical industry, Dietary supplement, VOC, Lobe, Medicine

GLEN MILLS, Pa., Sept. 21, 2023 /PRNewswire-PRWeb/ -- Pentec Health, Inc. (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).

Key Points: 
  • – Pentec Health, Inc. (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).
  • (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).
  • The initial availability of Altemia in select markets aligns with National Sickle Cell Awareness Month, which focuses on the need for research and treatment of SCD.
  • Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease.

SalioGen Therapeutics Appoints Jason F. Cole as Chief Executive Officer and Chairman of the Board of Directors

Retrieved on: 
Monday, September 11, 2023
Columbia University, Drug development, Gene, Bluebird, Regeneron Pharmaceuticals, Sickle cell disease, Cancer, Inherited disorders of trafficking, Public policy, Thalassemia, Finance, Dartmouth College, Government, Coding, Patient, Bluebird bio, Economic development, Chief business officer, Growth, Therapy, BLA, Management, MD

LEXINGTON, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company, today announced that its Board of Directors has appointed Jason F. Cole, J.D.

Key Points: 
  • LEXINGTON, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company, today announced that its Board of Directors has appointed Jason F. Cole, J.D.
  • Jason will also serve as Chairman of the Company’s Board of Directors and work closely with the leadership team to refine SalioGen’s corporate strategy and long-term vision as it advances its Gene Coding™ technology toward the clinic.
  • “The Board of Directors is excited to appoint a leader of Jason’s strategic abilities, talent, and financial acumen as the Company’s CEO,” said Paul B. Manning, interim Chief Executive Officer of SalioGen.
  • He currently serves as a Board Member at MassBIO where he advises on public policy and economic development.

Eric Kmiec, Ph.D., Named Editor-in-Chief of Gene and Genome Editing

Retrieved on: 
Wednesday, September 6, 2023
Kmiec, DNA, CRISPR, Gene, Augusta University, Genetics, Stanford University, Medical college, Gene editing, Pathology, Cancer, Medical College of Georgia, Inherited disorders of trafficking, Research, Lung, Master of Science, Knowledge, FDA, Therapy, Molecular medicine, Environment, Homologous recombination, Antibiotics, Vaccine

Wilmington, Delaware, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eric Kmiec, Ph.D., executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute , has been selected as editor-in-chief of the scientific journal Gene and Genome Editing .

Key Points: 
  • Wilmington, Delaware, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eric Kmiec, Ph.D., executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute , has been selected as editor-in-chief of the scientific journal Gene and Genome Editing .
  • “We have a unique opportunity to fill a void in the field by focusing on clear messages about the foundational aspects of gene editing and accepting papers that cover groundbreaking gene editing discoveries.”
    “I am delighted with Eric’s appointment and the plans he has to take the journal in a new direction,” said Susanne Steiginga, MSc, executive publisher of Gene and Genome Editing.
  • He is widely recognized for his pioneering work in the fields of molecular medicine and gene editing.
  • Throughout his professional career, Kmiec has led research teams in developing gene editing technologies and genetic therapies for inherited disorders and cancer.

A.O.U. San Giovanni di Dio Ruggi d'Aragona Expands Usage of SOPHiA GENETICS DDM™ Platform

Retrieved on: 
Thursday, August 17, 2023
Database, Workflow, Tumors of the hematopoietic and lymphoid tissues, NGS, Bone marrow, Inherited disorders of trafficking, Research, Biomarker, Sophia, Sophia Genetics, Data analysis, Patient, Machine learning, GENETICS, Medicine, Artificial intelligence, Diagnosis, Genome, Medical imaging

BOSTON and ROLLE, Switzerland, Aug. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that A.O.U. San Giovanni di Dio Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers, specifically Myeloma. The hospital, located on the western coast of Italy in Salerno, also leverages SOPHiA GENETICS technology to review rare and inherited disorders.   

Key Points: 
  • San Giovanni di Dio Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to advance its research and diagnosis of blood cancers, specifically Myeloma.
  • San Giovanni di Dio Ruggi d'Aragona Hematology Unit in using NGS testing for the first time.
  • San Giovanni di Dio Ruggi d'Aragona, can still find important biomarkers to research disorders and diagnose their patients.
  • San Giovanni di Dio Ruggi d'Aragona to retain ownership of its database, supporting the research team as it continues to increase its expertise.

Global Direct-to-Consumer Genetic Testing Market Report 2023: Sector is Expected to Reach $8.8 Billion by 2030 at a CAGR of 24.3% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 11, 2023
Health, Genetics, DTC, DNA, COVID-19, Inherited disorders of trafficking, Research, Genomics, USD, Ancestry.com, Market, Nutritional genomics, Risk, Genetic testing, Whole genome sequencing, Agriculture, Vaccine, Ancestor, Geneanet

The global direct-to-consumer genetic testing market size is expected to reach USD 8.8 billion by 2030, expandingat a CAGR of 24.3% from 2023 to 2030.

Key Points: 
  • The global direct-to-consumer genetic testing market size is expected to reach USD 8.8 billion by 2030, expandingat a CAGR of 24.3% from 2023 to 2030.
  • The major drivers of market growth include increasing awareness about the potential benefits of genetic testing, growing demand for personalized medicine, and decreasing the cost of genomic sequencing.
  • Moreover, the number of companies offering direct-to-consumer (DTC) genetic testing services has increased, offering consumers a wider range of options.
  • The marketplace is moderately fragmented, with a large number of medium and large-sized companies accounting for the majority revenue of the market.

Speaking up for the annoying fruit fly

Retrieved on: 
Friday, June 2, 2023
Columbia University, Gaps, Learning, Heart, Neuron, DNA, Human, Partnership, Genetics, Friends, Secret Life, Chocolate, ARD International Music Competition, Drosophila melanogaster, Nobel Prize, Sleep, Light, Physiology, Inherited disorders of trafficking, Aggression, Medicine, Research, Cell, DSM-IV codes, Reproduction, Science, Plant, Nobel Prize in Physiology or Medicine, Protein, Animal, Chromosome, Genome, Morgan, Biology, Knowledge, Growth, Personality, B cell, Gene, Memory, Wine, Female, Disease, Egg, Truffle, Agriculture, Pharmaceutical industry, Vaccine, Fly, Fruit, Drosophila

Fruit flies can be truly annoying when they are buzzing around your living room or landing in your wine.

Key Points: 
  • Fruit flies can be truly annoying when they are buzzing around your living room or landing in your wine.
  • But we have much to thank these tiny nuisances for – they revolutionised biological and medical science.
  • Flies and mosquitoes both belong to Diptera, the group of insects that have only two wings (from the Greek di meaning two and pteron meaning wing).
  • I will argue from a different angle, though, to win your respect for one specific dipteran: the fruit or vinegar fly (Drosophila melanogaster).

Helping science take off

    • This is because it’s easier to see evolutionary changes in large populations of a species with high turnover.
    • His mass-breeding experiments with hundreds of thousands of flies led to the discovery of a single fly with white eyes, instead of the red eyes fruit flies normally have.
    • The plethora of genetic strategies we’ve learned about in flies has turned into a powerful means to dissect mechanisms of fly development.
    • In 1995, three scientists won the Nobel prize for their contribution to this new understanding.

A startling likeness

    • Many human genes can even take over the function of their Drosophilia equivalent when inserted into the fly genome.
    • Because we are so alike genetically, many aspects of human biology and disease have been explored first in Drosophila.
    • Today, over 10,000 researchers worldwide are estimated to work with Drosophila in many areas of science that relate to human biology and disease.
    • Fruit flies hovering in your kitchen might be aggravating, but hopefully you will see them in a different light now.

SOPHiA GENETICS Celebrates Swiss Biotech Award

Retrieved on: 
Tuesday, April 25, 2023
Health Technology, Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Genetics, Artificial Intelligence, Other Technology, Biotechnology, Science, Software, Other Science, Research, Health, Partnership, Intuition, NGS, Cancer, Inherited disorders of trafficking, AstraZeneca, Qiagen, Sophia, Organization, Sophia Genetics, Agilent Technologies, Patient, Machine learning, GENETICS, Medicine, Artificial intelligence, Entrepreneurship, Ecosystem, Success, Award, Data science, Pharmaceutical industry

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association.

Key Points: 
  • SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association.
  • The Award recognizes SOPHiA GENETICS’ contributions in leading the way to democratizing data-driven medicine.
  • “SOPHiA GENETICS is not only revolutionizing the way researchers and clinicians are using data, but it is also breaking barriers to make this practice more accessible to all,” said Michael Altorfe, CEO, Swiss Biotech Association.
  • “SOPHiA GENETICS’ approach to healthcare is refreshing and it is for that reason that we recognize it as a Swiss Biotech Success Story.”
    The Swiss Biotech Success Stories Awards were launched in 2018 to illustrate how Swiss biotech companies help patients, improve healthcare worldwide, and make a valuable and significant contribution to the Swiss and global economies.

Genomics Market to Reach $94.86 Billion by 2030 at CAGR 16.5%: Grand View Research, Inc.

Retrieved on: 
Wednesday, April 19, 2023
Metagenomics, Survivor, CRISPR, Molecular epidemiology, Chromosome, Therapy, SARS-CoV-2, Genomics, National Centre for Disease Control, University of Cambridge, NGS, IHOP, National Cancer Institute, Pathway analysis, Inherited disorders of trafficking, Research, Genetic Alliance, Infection, OGL, DSM-IV codes, Biomarker, USD, Government, CDC, Whole genome sequencing, Revenue, Nature, SAN, Biomarker discovery, Functional genomics, Cancer, Merck & Co., Rare, Gene, Genetic disorder, Disease, Illumina, Inc., Antibiotics, Vaccine, Epigenomics

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to register a CAGR of 16.5% in the forecast period owing to the increasing demand for novel therapeutic and research applications in genomics.
  • Read full market research report more latest industry insights, " Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), By Deliverables, End-use, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global genomics market on the basis of application, deliverables, end-use, and region
    Genomics Market - Application & Technology Outlook (Revenue, USD Million, 2018 - 2030)